Loading...
Please wait, while we are loading the content...
Similar Documents
Losartan was more effective than atenolol for isolated systolic hypertension and left ventricular hypertrophy.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Rembold, Christopher M. |
| Copyright Year | 2003 |
| Abstract | Main results Analysis was by intention to treat. After adjustment for degree of LVH and Framingham risk score (sex, cholesterol, high density lipoprotein cholesterol, smoking, presence of diabetes and LVH, systolic BP, and body mass index) at baseline, groups did not differ for the composite endpoint (table) or MI. Cardiovascular mortality, stroke, all cause mortality, and new onset diabetes occurred less frequently in patients who received losartan than in those who received atenolol (table). Conclusion In patients with isolated systolic hypertension and left ventricular hypertrophy, losartan reduced cardiovascular mortality, stroke, all cause mortality, and new onset diabetes more than atenolol. |
| Starting Page | 37 |
| Ending Page | 37 |
| Page Count | 1 |
| File Format | PDF HTM / HTML |
| DOI | 10.1136/ebm.8.2.43 |
| Alternate Webpage(s) | http://ebm.bmj.com/content/ebmed/8/2/43.full.pdf |
| Alternate Webpage(s) | http://acpjc.acponline.org/Content/pdf/ACPJC-2003-138-2-037.pdf |
| PubMed reference number | 12614122 |
| Alternate Webpage(s) | https://doi.org/10.1136/ebm.8.2.43 |
| Volume Number | 138 |
| Issue Number | 2 |
| Journal | ACP journal club |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |